Literature DB >> 10491967

Second messengers, the substantia gelatinosa and injury-induced persistent pain.

K R Petersen-Zeitz1, A I Basbaum.   

Abstract

Although there is now unequivocal evidence that the circuitry within the substantia gelatinosa is a major contributor to the transmission and control of nociceptive messages, this was not known 35 years ago, when Pat Wall first focussed attention on this region. In addition to being the target of neurochemically distinct nociceptors, this region contains a heterogeneous population of excitatory and inhibitory interneurons. This review focuses on the contribution of second messenger systems that are found in the substantia gelatinosa. In particular the review highlights their critical contribution to the development of persistent pain conditions in the setting of tissue and nerve injury. Several of the studies used animals with deletions of genes that encode major second messenger molecules, including protein kinase A, C and nitric oxide synthase. Our laboratory has shown that mice with a deletion of the gene that encodes the gamma isoform of protein kinase C (which is almost exclusively expressed in a population of interneurons of the inner part of the substantia gelatinosa) have completely normal acute pain responses. However, the allodynia that characteristically develops after injury does not occur in these mice, particularly when it is generated by partial sciatic nerve injury. By contrast, deletion of genes that encode protein kinase A subunits only show deficits in the development of tissue inflammation-induced pain. These differences highlight the selectivity that characterizes the contribution of different second messenger molecules. Because of the restricted distribution of these molecules, it is likely that they are activated by different populations of primary afferent nociceptor and under very different conditions of injury. Understanding the circuitry within the substantia gelatinosa is thus critical to elucidating the mechanisms through which these second messenger molecules contribute to the development of persistent pain in the setting of injury.

Entities:  

Mesh:

Year:  1999        PMID: 10491967     DOI: 10.1016/s0304-3959(99)00132-3

Source DB:  PubMed          Journal:  Pain        ISSN: 0304-3959            Impact factor:   6.961


  6 in total

1.  Metabotropic glutamate receptor 5 upregulation in A-fibers after spinal nerve injury: 2-methyl-6-(phenylethynyl)-pyridine (MPEP) reverses the induced thermal hyperalgesia.

Authors:  Lindsey J Hudson; Stuart Bevan; Kara McNair; Clive Gentry; Alyson Fox; Rainer Kuhn; Janet Winter
Journal:  J Neurosci       Date:  2002-04-01       Impact factor: 6.167

Review 2.  The nociceptive and anti-nociceptive effects of bee venom injection and therapy: a double-edged sword.

Authors:  Jun Chen; William R Lariviere
Journal:  Prog Neurobiol       Date:  2010-06-15       Impact factor: 11.685

3.  Electrical stimulation of low-threshold afferent fibers induces a prolonged synaptic depression in lamina II dorsal horn neurons to high-threshold afferent inputs in mice.

Authors:  Andrei D Sdrulla; Qian Xu; Shao-Qiu He; Vinod Tiwari; Fei Yang; Chen Zhang; Bin Shu; Ronen Shechter; Srinivasa N Raja; Yun Wang; Xinzhong Dong; Yun Guan
Journal:  Pain       Date:  2015-06       Impact factor: 7.926

Review 4.  Understanding LTP in pain pathways.

Authors:  Jürgen Sandkühler
Journal:  Mol Pain       Date:  2007-04-03       Impact factor: 3.395

5.  An in vivo mouse model of long-term potentiation at synapses between primary afferent C-fibers and spinal dorsal horn neurons: essential role of EphB1 receptor.

Authors:  Wen-Tao Liu; Yuan Han; Hao-Chuan Li; Brandt Adams; Ji-Hong Zheng; Yong-Ping Wu; Mark Henkemeyer; Xue-Jun Song
Journal:  Mol Pain       Date:  2009-06-12       Impact factor: 3.395

6.  PKA and ERK, but not PKC, in the amygdala contribute to pain-related synaptic plasticity and behavior.

Authors:  Yu Fu; Jeong Han; Titilope Ishola; Michelle Scerbo; Hita Adwanikar; Cara Ramsey; Volker Neugebauer
Journal:  Mol Pain       Date:  2008-07-16       Impact factor: 3.395

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.